|
|
Phase III Randomized Study of an Opioid Titration Order Sheet Versus Standard Care in Patients With Cancer-Related Pain
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Supportive care
|
|
|
|
Active
|
|
|
|
21 and over
|
|
|
|
NCI
|
|
|
|
VU-VICC-SUPP-0424 VICCSUPP0424, VU-VICC-040410, NCT00666211
|
|
|
Objectives - To examine the effect of an opioid titration order sheet on pain outcomes.
- To examine the effect of an opioid titration order sheet on secondary outcomes of function, mood, and quality of life.
Entry Criteria Disease Characteristics:
- Histologically confirmed carcinoma
- Cancer-related pain requiring fixed-dose opioid therapy
- Has received ≥ 1 week of fixed-dose opioid therapy AND meets any of the following criteria:
- Inadequate pain control as defined by the patient
- Requires 2 or more rescue doses per day
- Requires adjustments in pain regimen (either fixed or breakthrough dosing)
- No pain crisis that requires hospitalization or immediate anesthetic or neurosurgical intervention
- No predominantly neuropathic pain (e.g., peripheral neuropathy) as assessed by the treating physician
Prior/Concurrent Therapy:
- See Disease Characteristics
- Concurrent chemotherapy or radiotherapy allowed
Patient Characteristics:
- ECOG performance status 0-2
- ANC > 1,500/mm³
- Platelet count > 100,000/mm³
- Serum bilirubin < 1.5 mg/dL
- Serum creatinine < 2.5 mg/dL
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Nutritional, pulmonary, and cardiac status must be considered adequate to tolerate the proposed study therapy
- Must be available for active follow-up
- No documented active psychiatric disorder (i.e., psychosis or major depression) that would preclude informed consent or the patient’s ability to comply with study procedures
- No significant infection
- No concerns about compliance with medication regimens or medical follow-up
- No excessive alcohol use
Expected Enrollment 128Outcomes Primary Outcome(s)Pain, including intensity, duration, and pain-related distress
Secondary Outcome(s)Function Mood Quality of life
Outline This is a multicenter study. Participating centers are randomized to 1 of 2 treatment arms. - Arm I (usual care): After completion of baseline assessments, patients undergo a standardized pain education program over approximately 15 minutes. The program consists of standard written materials about communicating pain to providers, opioids and side effect management, as well as a tailored discussion about patient concerns and specific information about prescribed opioid medications. Patients are also instructed in the use of the daily pain diary. Patients are then discharged from the clinic with instructions to contact the treating physician (through standard procedures) for problems with pain or side effects. The study staff conducts weekly telephone interviews to prevent changes in patient pain management practice. The treating physician continues to manage pain in their usual manner.
- Arm II (opioid titration order sheet): After completion of baseline assessments, patients undergo the standardized pain education program and are instructed in the use of the daily pain diary as described in arm I. The treating physician signs an Opioid Titration Order Sheet (OTOS) providing a baseline dose and schedule. The OTOS is faxed to study staff and verified. Patients are then discharged from the clinic with instructions to contact the research nurse for problems with pain or side effects. The treating physician also contacts the study staff if he/she is made aware of any problems pertaining to the patient’s pain control. The research nurse, in consultation with study physician, manages pain according to the OTOS and manages opioid side effects using standing orders. Referral to the treating physician is made as needed.
Patients' pain is managed on study for 8 weeks in the absence of unacceptable toxicity, pain crisis, or new site of pain. Patients complete a demographic questionnaire at baseline and other questionnaires at 2, 4, and 6 weeks (over the telephone) and at 8 weeks (at site or by telephone), including the Functional Assessment Screening Questionnaire (FASQ), the Brief Pain Inventory-Interference (PPI-I), The Profile of Mood States-Short Form (POMS-SF), and the Quality of life (FACT-G) questionnaire. Patients also complete a pain diary recording daily measures of pain dimensions, analgesic use (i.e., fixed dose opioids, rescue doses, and non-opioids), adjuvant medications, and side effects that prevented the patient from taking medications. Data in the pain diary is transcribed over the telephone on a weekly basis. Clinical data, including the type of cancer, stage of disease, time since diagnosis, current treatment for cancer, type of pain, time since onset of pain, and time of first opioid prescription, as well as information regarding analgesics (opioid and non-opioid), adjuvant medications, and medications to manage side effects prescribed during the study is collected from patients' medical records. Anticancer and palliative treatment received during the study is monitored via treating physician records. The physician charts are reviewed after study completion to determine whether pain, treatment, and response are adequately documented and treated. The documentation in the physician charts is compared to the documentation obtained by the study staff during the study.
Trial Contact Information
Trial Lead Organizations Vanderbilt-Ingram Cancer Center | | | Nancy Wells, DNSc, RN, Principal investigator | | | | Mary Dietrich, Study coordinator | | | | Tony Hudson, Study coordinator | | | | Patty Hendricks, Study coordinator | | | | Hannah Spahr, Study coordinator | | | | Trial Sites
|
|
|
|
U.S.A. |
|
Kentucky |
|
|
Owensboro |
|
| | | | | | | | Mitchell Memorial Cancer Center at Owensboro Medical Health System |
| | Contact Person | Ph: | 270-688-3600 | | 800-947-7102 |
|
|
Tennessee |
|
|
Chattanooga |
|
| | | Erlanger Cancer Center at Erlanger Hospital - Baroness |
| | Clinical Trials Office - Erlanger Cancer Center | |
|
|
Nashville |
|
| | MBCCOP - Meharry Medical College - Nashville |
| | Contact Person | |
| | Vanderbilt-Ingram Cancer Center |
| | Clinical Trials Office - Vanderbilt-Ingram Cancer Center | |
| | Vanderbilt-Ingram Cancer Center - Cool Springs |
| | Nancy Wells | |
| | Vanderbilt-Ingram Cancer Center at Franklin |
| | Nancy Wells | |
|
Registry Information | | Official Title | | Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients with Cancer Related Pain. | | Trial Start Date | | 2005-05-19 | | Trial Completion Date | | 2011-05-19 (estimated) | | Registered in ClinicalTrials.gov | | NCT00666211 | | Date Submitted to PDQ | | 2008-04-18 | | Information Last Verified | | 2008-12-18 | | NCI Grant/Contract Number | | CA68485 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|